USA - NASDAQ:IRON - US2546041011 - Common Stock
The current stock price of IRON is 87 USD. In the past month the price increased by 22.97%. In the past year, price increased by 33.85%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.18 | 386.95B | ||
| AMGN | AMGEN INC | 14.43 | 169.90B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.98 | 106.72B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.37 | 68.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 863.71 | 57.74B | ||
| ARGX | ARGENX SE - ADR | 63.46 | 52.40B | ||
| INSM | INSMED INC | N/A | 39.25B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.37 | 36.51B | ||
| NTRA | NATERA INC | N/A | 27.24B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.85B | ||
| BIIB | BIOGEN INC | 9.36 | 22.98B |
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company is headquartered in Watertown, Massachusetts and currently employs 84 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
DISC MEDICINE INC
321 Arsenal Street, Suite 101
Watertown MASSACHUSETTS US
Employees: 84
Phone: 16176749274
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company is headquartered in Watertown, Massachusetts and currently employs 84 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
The current stock price of IRON is 87 USD. The price decreased by -1.48% in the last trading session.
IRON does not pay a dividend.
IRON has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
IRON stock is listed on the Nasdaq exchange.
DISC MEDICINE INC (IRON) will report earnings on 2025-11-06, before the market open.
You can find the ownership structure of DISC MEDICINE INC (IRON) on the Ownership tab.
ChartMill assigns a technical rating of 9 / 10 to IRON. When comparing the yearly performance of all stocks, IRON is one of the better performing stocks in the market, outperforming 91.71% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to IRON. While IRON seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months IRON reported a non-GAAP Earnings per Share(EPS) of -4.47. The EPS decreased by -24.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.86% | ||
| ROE | -23.67% | ||
| Debt/Equity | 0.05 |
18 analysts have analysed IRON and the average price target is 111.09 USD. This implies a price increase of 27.69% is expected in the next year compared to the current price of 87.